title: Rationale for early treatment of polycystic kidney disease.
abstract: In hereditary cystic disorders, renal injury begins with the formation of the first cyst. Renal injury may manifest as large kidneys, abdominal pain, hypertension and hematuria in children and young adults with autosomal dominant polycystic kidney disease (ADPKD). In autosomal recessive PKD (ARPKD) and ADPKD, cysts form primarily in collecting ducts and expand progressively. Collecting duct cysts that block urine flow have the potential to block urine formation in large numbers of upstream nephrons. In an ARPKD rat congenitally lacking vasopressin, only a few cysts developed until exogenous arginine vasopressin (AVP) was administered. AVP elevates cyclic AMP in vulnerable tubule cells to stimulate mitogenesis and fluid secretion, thereby causing cysts to form and enlarge indefinitely. The administration of an AVP-V2 receptor inhibitor or the consumption of sufficient water to persistently lower plasma AVP levels will ameliorate disease progression. Renal volume measurements provide the most reliable way to forecast long-term outcome in individual children and adult patients with ADPKD. Many drugs that have demonstrated efficacy in small clinical trials, preclinical trials and cell-based studies are in the treatment pipeline. Counseling, regular exercise, limitation of dietary calories, salt, protein and fat, increased fluid intake throughout the day and treatment of hypertension are components of a rational treatment program that can be offered at an early age to those with, or at risk for developing PKD.
authors.affiliation: The Kidney Institute, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS, 66160, USA, Jgrantha@kumc.edu.
authors.forename: Jared J
authors.initials: JJ
authors.lastname: Grantham
mesh_terms: D000328:Adult; D000818:Animals; D002648:Child; D018450:Disease Progression; D042241:Early Diagnosis; D006801:Humans; D007690:Polycystic Kidney Diseases / Q000235:genetics / Q000473:pathology / Q000628:therapy*; D016891:Polycystic Kidney, Autosomal Dominant / Q000235:genetics / Q000473:pathology / Q000628:therapy; D017044:Polycystic Kidney, Autosomal Recessive / Q000235:genetics / Q000473:pathology / Q000628:therapy; D051381:Rats; D050396:TRPP Cation Channels / Q000235:genetics
chemical_list: D050396:TRPP Cation Channels